Novo Nordisk CEO Lars Fruergaard Jorgensen expressed confidence in the potential for long-term use of the company’s drug Wegovy, suggesting that its users could exhibit more sustained adherence compared to earlier weight-loss medications.

At the annual JP Morgan Healthcare Conference in San Francisco, Jorgensen mentioned that he anticipates individuals to remain committed to Wegovy due to its efficacy. While acknowledging that it might be too early to make conclusive statements, he emphasized the possibility of coexistence between injectable and oral weight-loss medications in the market.

According to Reuters, a recent study revealed that 40% of individuals prescribed Wegovy in 2021 or 2022 were still using the medication a year later, signifying an adherence rate more than three times higher than that of older weight-loss drugs.

Wegovy, an injectable drug, shares its key ingredient with Novo Nordisk’s Ozempic. Both medications belong to the GLP-1 class, which includes Eli Lilly’s diabetes drug Mounjaro and weight-loss medication Zepbound.